Magnera (NYSE:MAGN) Stock

Magnera

Magnera Corp formerly Glatfelter Corporation manufactures and sells a variety of paper and fiber products. The company's reportable segments are; Composite Fibers, Spunlace. and Airlaid Materials. The Airlaid Materials segment which is also its key revenue generating segment, is a supplier of cellulose-based airlaid nonwoven materials used to manufacture consumer products for end-user markets. The Airlaid Materials segment produces materials used in feminine hygiene, specialty wipes, tabletop, home care, and other consumables. Geographically, the company derives majority of its revenue from Americas and rest from Europe, Middle East, Africa and Asia Pacific markets.

Magnera Corp

MAGNETIC RESOURCES NL by Magnetic Resources NL

MAGNOLIA BANCORP INC by Magnolia Bancorp, Inc.

MAGNUM OPUS ACQUISITION LTD CL A

Magna Gold Corp Ordinary Shares

Magna International Inc

Magna Mining Inc

MAGNA TERRA MINERALS INC by Magna Terra Minerals Inc.

Magna Terra Minerals Inc

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor Corp

Magnet Forensics Inc Sub Voting

MAGNETIC NRTH ACQUISITION by Magnetic North Acquisition Corp.

Magnetic North Acquisition Corp

MAGNETITE MINES LTD by Magnetite Mines Ltd.

Magnetite Mines Ltd

MAGNIS ENERGY TECH LTD by Magnis Energy Technologies Ltd.

Magnis Energy Technologies Ltd

Magnite Inc

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas Corp

Magnora ASA

MAGNUM GOLDCORP INC by Magnum Goldcorp Inc.

Magnum Goldcorp Inc

MAGNUM MINING AND EXPLTN by Magnum Mining and Exploration Limited

Magnum Mining and Exploration Ltd

Needham analyst Quinn Bolton reiterates Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Buy and maintains $16 price target.

News

Price Target

Reiteration

Analyst Ratings

CRNC

Needham Reiterates Buy on Cerence, Maintains $16 Price Target

<a href="https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html" title="https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html">https://www.cnbc.com/2025/03/18/teslas-china-rival-zeekr-to-roll-out-free-advanced-driver-assistance.html</a>

TSLA

CNBC: 'Tesla's China rival Zeekr to roll out advanced driver assistance-system for free'

William Blair analyst Y Katherine Xu downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Outperform to Market Perform.

Downgrades

INCY

William Blair Downgrades Incyte to Market Perform

MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 24 percent. This is a 287.5 percent decrease over losses of $(0.16) per share from the same period last year.

Earnings

Earnings Misses

INKT

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.09 by 711.11 percent. This is a 153.68 percent increase over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $437.822 million which beat the analyst consensus estimate of $424.001 million by 3.26 percent. This is a 14.12 percent decrease over sales of $509.784 million the same period last year.

Earnings Beats

IHS Holding Q4 2024 GAAP EPS $0.73 Beats $0.09 Estimate, Sales $437.822M Beat $424.001M Estimate

<ul>
<li>The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company's existing capped call transactions relating to the Company's existing 0.375% Convertible Senior Notes due 2026 (the "Convertible Senior Notes"), (i) to finance the redemption, repurchase, repayment, satisfaction, and discharge or other payment of all or a portion of the Convertible Senior Notes, which may include one or more repurchases pursuant to privately negotiated transactions, and the payment of accrued and unpaid interest thereon, (ii) to pay any fees, costs, and expenses relating to the offering of the Notes and Credit Agreement transactions described below and/or (iii) for general corporate purposes. The Notes offering is subject to market and other conditions, and may not occur as described or at all.</li>
<li>The Company also today announced its intention to amend its existing Credit Agreement to, among other things, extend the maturity of the Company's revolving credit facility from 2028 to 2030 and increase the amount of revolving credit commitments by up to $200 million (resulting in aggregate commitments of up to $500 million). The terms of the commitments and loans under the amended revolving credit facility are expected to be substantially similar to those relating to the commitments and loans under the existing revolving credit facility, except with respect to the aggregate amount of commitments thereunder, the maturity date thereof and certain other terms. The Credit Agreement amendments are subject to market and other conditions, and may not occur as described or at all. The consummation of the Notes offering is not conditioned on the consummation of the Credit Agreement amendments and the consummation of the Credit Agreement amendments are not conditioned on the consummation of the Notes offering</li>
</ul>

Health Care

Financing

General

PODD

Insulet Intends To Offer $450M Principal Amount Of Senior Unsecured Notes Due 2033 In A Private Placement

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Guidance

USEA

United Maritime Says Long-term Fundamentals Of Dry Bulk Market Remain Strong

Biotech

PYXS

As Of December 31, 2024, Pyxis Oncology Had Cash And Cash Equivalents Of $128.4M That Is Expected To Provide Cash Runway Into The Second Half Of 2026

Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $16.15 million which beat the analyst consensus estimate of $13.81 million by 16.89 percent.

Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

UBS analyst Steven Fisher downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announces $108 price target.

PCAR

UBS Downgrades PACCAR to Neutral, Announces $108 Price Target

NCNO

Sandbox Banking's Glyue Introduced In The Zoom App Marketplace

United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.41) by 80.49 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $10.80 million which beat the analyst consensus estimate of $9.50 million by 13.68 percent. This is a 6.90 percent decrease over sales of $11.60 million the same period last year.

United Maritime Q4 2024 Adj EPS $(0.08) Beats $(0.41) Estimate, Sales $10.80M Beat $9.50M Estimate

VRAX

Virax Biolabs Enrolls First Patients In Its UK Based Clinical Study Assessing T Cell Dysfunction In Post-acute Infection Syndromes

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.53) by 66.04 percent. This is a 70 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $22.60 million which beat the analyst consensus estimate of $4.28 million by 428.04 percent. This is a 706.85 percent increase over sales of $2.80 million the same period last year.

STOK

Stoke Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.53) Estimate, Sales $22.60M Beat $4.28M Estimate

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $64 to $66.

RYTM

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $66

Chinese EV maker&nbsp;XPeng&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading lower premarket on Tuesday. The company reported&nbsp;fiscal&nbsp;fourth-quarter sales growth of&nbsp;23.4%&nbsp;year-on-year to 16.11 billion Chinese Yuan&nbsp;($2.21&nbsp;billion), topping the&nbsp;consensus estimate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44372075/xpeng-reports-fourth-quarter-and-fiscal-year-2024-unaudited-financial-results" rel="noreferrer noopener">of&nbsp;16.02 billion Chinese Yuan</a>.&nbsp;
Total revenues increased 59.4% sequentially in the quarter. The Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival's quarterly vehicle deliveries increased 52.1% Y/Y to 91,507. XPeng's physical sales network had 690 stores, covering 226 cities as of December 31, 2024.
XPeng's self-operated charging station network reached 1,920 stations as of December 31, 2024. Revenues from vehicle sales increased 20.0% Y/Y to 14.67 billion Chinese Yuan ($2.01 billion) on higher deliveries.
Gross margin was 14.4% versus 6.2% a year ago. Vehicle margin was 10.0% versus 4.1% a year ago, primarily attributable to the cost reduction. Operating loss for the quarter was 1.56 billion Chinese Yuan ($0.21 billion). 
Adjusted net loss per ADS of 1.47 Chinese Yuan missed the analyst consensus estimate for a loss of 1.35 Chinese Yuan. In USD terms, the adjusted earnings <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">per ADS was a loss of 20 cents</a> in-line with the consensus of 20 cents loss.
The&nbsp;company held&nbsp;$5.75 billion&nbsp;in cash and equivalents&nbsp;as of December 31, 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/03/44240449/tesla-rival-xpeng-eyes-138-billion-investment-in-humanoid-robots-says-chinese-state-media" rel="noreferrer noopener">Tesla Rival XPeng Eyes $13.8 Billion Investment In Humanoid Robots, Says Chinese State Media</a>
Chairman and CEO of XPENG, Xiaopeng He, highlighted the company&#8217;s strategic positioning to expand its market share in the Smart EV sector both in China and internationally.
He emphasized that AI will play a crucial role in advancing L3 and L4 autonomous driving within the automotive industry. The company&#8217;s goal is to establish XPENG as a globally recognized AI-driven automotive company and a smart technology brand that resonates with users worldwide.
Outlook: XPENG projects first-quarter vehicle deliveries between 91,000 and 93,000, reflecting <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">a surge of 317% to 326.8% Y/Y</a>.
The company anticipates revenue of 15 billion Chinese Yuan to 15.7 billion Chinese Yuan, vs. the consensus of 14.684 billion Chinese Yuan.
Investors can gain exposure to the stock via&nbsp;VanEck Low Carbon Energy ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMOG#NYSE">SMOG</a>) and Invesco WilderHill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>).
Price Action: XPEV shares are down 0.49% at $24.44 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44267567/xpeng-hesai-group-kohls-groupon-and-tesla-why-these-5-stocks-are-on-investors-radars-today" target="_blank" rel="noreferrer noopener">Xpeng, Hesai Group, Kohl&#8217;s, Groupon, And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Movers

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SMOG

XPEV

Tesla's China Rival XPeng Delivers Over 91,500 EVs In Q4, Eyes Massive Growth In Q1

UBS analyst Brian Meredith upgrades Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) from Neutral to Buy and raises the price target from $344 to $395.

Upgrades

UBS Upgrades Willis Towers Watson to Buy, Raises Price Target to $395

HC Wainwright &amp; Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Buy and raises the price target from $11 to $12.

BDTX

HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12

ADTX

Appili Therapeutics Submits Applications For Four New Federal Funding Opportunities

Press Releases

Berry Completes Spin-Off and Merger of its Health, Hygiene and Specialties Global Nonwovens and Films Business

Magnera Emerges as a New Global Leader in the Specialty Materials and Nonwovens Industry, Following the Merger of Berry's Health, Hygiene and Specialties Global Nonwovens and Films Business with Glatfelter

Comments

Magnera

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL